Biomarker Discovery and Analysis Platforms
Broad Clinical Labs is committed to supporting breakthroughs in translational and clinical research that better human health. Our comprehensive biomarker discovery platform covers insights from common point mutations to intricate gene expression profiles, enabling both exploratory and targeted biomarker research across preclinical and population cohorts.
Applications of Biomarker Research and Discovery
Drug Discovery: Identifying new drug targets and biomarkers for therapeutic development.
Clinical Trials: Validating biomarkers and stratifying patients.
Precision Medicine: Developing personalized treatments based on individual genetic profiles.
Disease Diagnosis and Prognosis: Improving early detection and predicting disease outcomes.
Population Health: Understanding disease prevalence and risk factors within specific populations.
Types of Biomarkers
Pharmacodynamic
Monitoring
Diagnostic
Prognostic
Safety
Predictive
Risk
Sequencing Solutions for Biomarker Discovery and Research
We offer sequencing services to power every stage of the drug development pipeline and to complement a diverse set of research and clinical applications. Learn more about our relevant services, and reach out to our team for personalized recommendations. We scale our sequencing services to meet the needs of your project and offer analytical support from start to finish.
Comprehensive Sequencing Services
Whole Genome Sequencing
• Treatment response biomarkers
• Research Short-read, Research Long-read, and Clinical Short-read available
Blended Genome-Exome Sequencing
• Research and Clinical BGE available
RNA Sequencing
• Stranded mRNA, Total RNA, and Transcriptome Capture, and SmartSeq2 available
Plasma Proteomic Profiling
• Olink® Explore HT assay available
Whole Exome Sequencing
• Homologous recombination repair deficiency
• Microsatellite instability
• Research germline, Research somatic, and Clinical somatic available
Single Cell Sequencing
• Monitoring biomarkers of drug response and disease progression
• 10x Single Cell Gene Expression (3' or 5'), and 10x Genomics Single Cell Multiome available
Whole Genome Sequencing
• Treatment response biomarkers
• Research Short-read, Research Long-read, and Clinical Short-read available
Blended Genome-Exome Sequencing
• Research and Clinical BGE available
RNA Sequencing
• Stranded mRNA, Total RNA, and Transcriptome Capture available
Plasma Proteomic Profiling
• Olink® Explore HT assay available
Whole Exome Sequencing
• Homologous recombination repair deficiency
• Microsatellite instability
• Research germline, Research somatic, and Clinical somatic available
Single Cell Sequencing
• Monitoring biomarkers of drug response and disease progression
• 10x Single Cell Gene Expression (3' or 5'), 10x Genomics Single Cell Multiome, and SmartSeq2 available
Whole Genome Sequencing
- Novel prognostic/diagnostic biomarkers
- Treatment response biomarkers
- Research Short-read, Research Long-read, and Clinical Short-read available
Blended Genome-Exome Sequencing
- Low-pass WGS and deep WES combined for integrated insights
- Research and Clinical BGE available
RNA Sequencing
- Gene expression, alternative transcripts or splicing events
- Stranded mRNA, Total RNA, and Transcriptome Capture available
Plasma Proteomic Profiling
- Protein biomarkers: inflammatory, organ-specific, drug targets
- Olink® Explore HT assay available
Whole Exome Sequencing
- Tumor mutational burden
- Homologous recombination repair deficiency
- Microsatellite instability
- Research germline, Research somatic, and Clinical somatic available
Single Cell Sequencing
- Biomarkers for patient stratification
- Monitoring biomarkers of drug response and disease progression
- 10x Single Cell Gene Expression (3' or 5'), 10x Genomics Single Cell Multiome, and SmartSeq2 available
Advanced Data Analysis:
- Cutting edge analytical techniques from the Methods Development Lab (e.g. isoform sequencing)
- Easily accessible, standardized bioinformatic pipelines and tools
- Collaborative results delivery and interpretation
Quality Assurance and Control:
- Rigorous quality control measures
- Laboratory CLIA Certification and CAP Accreditation
- Backed by 30+ years of expertise in the Broad community and beyond
Benefits of Partnering with
Broad Clinical Labs
Full-service platform:
We support multiomic projects from conception to clinical implementation.
High-quality data:
Accurate and reliable results for your research.
Timely delivery:
Rapid turnaround times to accelerate your projects.
Expertise:
Access to a team of experienced scientists and technicians.
Scalability:
High-throughput solutions to meet your specific needs.
Frequently Asked Questions: Biomarker Discovery Platform
What does Broad Clinical Labs' biomarker discovery platform include?
The Broad Clinical Labs biomarker discovery platform brings six services together under one provider: whole genome sequencing, Blended Genome-Exome sequencing, whole exome sequencing, RNA sequencing, single cell sequencing, and plasma proteomic profiling. It supports exploratory and targeted biomarker research across preclinical and population cohorts. Analytical support runs from project start to finish. Samples are processed in BCL’s CLIA-certified and CAP-accredited laboratory.
Which sequencing service fits each type of biomarker?
- Whole genome sequencing: novel prognostic, diagnostic, and treatment response biomarkers
- Whole exome sequencing: tumor mutational burden, homologous recombination repair deficiency, and microsatellite instability
- RNA sequencing: gene expression, alternative transcripts, and splicing events
- Plasma proteomic profiling: inflammatory, organ-specific, and drug target proteins
- Single cell sequencing: biomarkers for patient stratification and monitoring of drug response and disease progression
Can Broad Clinical Labs support polygenic risk scores research?
Broad Clinical Labs generates the sequencing data used to develop and apply polygenic risk scores. Research Blended Genome-Exome Sequencing supports GWAS and PRS development, with improved imputation accuracy compared with genotyping arrays. Clinical Blended Genome-Exome Sequencing produces data for combined monogenic and polygenic risk analysis. In Mass General Brigham’s cardiovascular risk test, BCL performs the cBGE assay and the Laboratory for Molecular Medicine interprets results.
What data analysis support comes with the biomarker discovery platform?
The Broad Clinical Labs biomarker discovery platform includes three kinds of analysis support: standardized bioinformatic pipelines, collaborative results delivery and interpretation, and advanced techniques from BCL’s Methods Development Lab. One example of those techniques is long-read RNA isoform sequencing. Contact the BCL team for project-specific recommendations.
How does Broad Clinical Labs protect and handle my multi-omic sequencing data?
As a CLIA-certified laboratory operating under the rigorous standards of the Broad Institute, Broad Clinical Labs is held to a level of oversight that directly protects you, your data, and your patients. Broad Clinical Labs protects your data inside a regulated security boundary built on NIST 800-53-compliant systems. Your data belongs to you and is returned to you. We do not sell participant data or use it beyond what is needed to deliver your services, and we retain only what regulatory obligations require.
Ready to get started?
See our full list of services to find the right one for your project



